Equity Profile

TVTX

Travere Therapeutics, Inc.

Health CareBiotechnology$5.8B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Travere Therapeutics, Inc. (TVTX) is a biotechnology company focused on developing therapies for rare diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.

$0.05

Revenue Growth

Revenue figures will indicate how well the company is expanding its market presence and whether its products are gaining traction.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

TVTX Q2-2026 Earnings Preview

Context

Company Snapshot

Travere Therapeutics, Inc. (TVTX) is a biotechnology company focused on developing therapies for rare diseases. With a market cap of $6 billion, it plays a crucial role in the healthcare sector, particularly in addressing unmet medical needs for patients with serious conditions.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+253.42%

Avg Stock Reaction

+0.68%

Last Quarter Recap

In Q1 2026, Travere reported an EPS of $0.05, significantly beating expectations by 116.78%. The stock reacted positively, gaining 1.79% the following day.

Management Promises & Guidance

Management committed to continuing its focus on rare disease therapies.
They indicated plans for potential new product launches in the upcoming quarters.

Expectations

Wall Street Expectations

Overall, expectations are mixed as Travere has consistently beaten EPS estimates in recent quarters, but revenue guidance remains unclear.

Bull Case

If Travere maintains its strong EPS performance and shows robust revenue growth, it could signal a solid upward trend for the stock.

Bear Case

Concerns about revenue stagnation or a failure to meet high expectations could lead to a negative market reaction.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.05

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.

Revenue Growth

N/A

Revenue figures will indicate how well the company is expanding its market presence and whether its products are gaining traction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected EPS for Q2 2026?

Given the company's history of exceeding EPS estimates, this figure will be crucial for investor confidence.

What are the revenue projections for the upcoming quarter?

Revenue growth is essential for assessing the company's market position and future potential.

Edge

What the Street Is Missing

Why consensus could be wrong

Despite the strong EPS surprises, the Street may be underestimating the potential for revenue growth in rare disease therapies.

Supporting Evidence

The company's consistent ability to beat EPS estimates suggests operational strength.

Options pricing indicates a higher expected move than historical averages, reflecting potential for significant news.

Key Risk

If revenue growth exceeds expectations, it could shift the narrative significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be critical in determining whether Travere can sustain its positive momentum or if it will face challenges.

Bull Confirmed If

An EPS of $0.10 or higher would confirm the bull case, indicating strong profitability.

Bear Confirmed If

An EPS below $0.05 would suggest a potential downturn in investor sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±20.03%

Historical Avg

±2.2%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings report.

Options are pricing ±20.0% while TVTX has averaged ±2.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

43.7%

Calls (138K)P/C Ratio: 0.20Puts (23K)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

115.25%

of float

Insider

0.76%

of float

Holders

380

institutions

Top Holders· as of Dec 2025

Janus Henderson Group PLC
10,511,166 sh · $425.7M
11.38%
-0.8%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Travere beats expectations, history suggests the stock could rise by around 0.68%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further clarity.

Miss

A miss could lead to a decline, with historical patterns indicating a potential drop of around 1.10%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or pipeline developments.
2Management's commentary on market conditions and competitive landscape.
3Details on revenue growth strategies and targets.
4Insights into patient feedback on existing therapies.
5Future guidance on EPS and revenue expectations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Travere Therapeutics, Inc. (TVTX) is a biotechnology company focused on developing therapies for rare diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.

$0.05

Revenue Growth

Revenue figures will indicate how well the company is expanding its market presence and whether its products are gaining traction.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

TVTX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+253.42%

Avg Stock Reaction

+0.68%

Last Quarter Recap

In Q1 2026, Travere reported an EPS of $0.05, significantly beating expectations by 116.78%. The stock reacted positively, gaining 1.79% the following day.

Management Promises & Guidance

Management committed to continuing its focus on rare disease therapies.
They indicated plans for potential new product launches in the upcoming quarters.

Expectations

Wall Street Expectations

Overall, expectations are mixed as Travere has consistently beaten EPS estimates in recent quarters, but revenue guidance remains unclear.

Bull Case

If Travere maintains its strong EPS performance and shows robust revenue growth, it could signal a solid upward trend for the stock.

Bear Case

Concerns about revenue stagnation or a failure to meet high expectations could lead to a negative market reaction.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.05

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.

Revenue Growth

N/A

Revenue figures will indicate how well the company is expanding its market presence and whether its products are gaining traction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected EPS for Q2 2026?

Given the company's history of exceeding EPS estimates, this figure will be crucial for investor confidence.

What are the revenue projections for the upcoming quarter?

Revenue growth is essential for assessing the company's market position and future potential.

Edge

What the Street Is Missing

Why consensus could be wrong

Despite the strong EPS surprises, the Street may be underestimating the potential for revenue growth in rare disease therapies.

Supporting Evidence

The company's consistent ability to beat EPS estimates suggests operational strength.

Options pricing indicates a higher expected move than historical averages, reflecting potential for significant news.

Key Risk

If revenue growth exceeds expectations, it could shift the narrative significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be critical in determining whether Travere can sustain its positive momentum or if it will face challenges.

Bull Confirmed If

An EPS of $0.10 or higher would confirm the bull case, indicating strong profitability.

Bear Confirmed If

An EPS below $0.05 would suggest a potential downturn in investor sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±20.03%

Historical Avg

±2.2%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings report.

Options are pricing ±20.0% while TVTX has averaged ±2.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

43.7%

Calls (138K)P/C Ratio: 0.20Puts (23K)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

115.25%

of float

Insider

0.76%

of float

Holders

380

institutions

Top Holders· as of Dec 2025

Janus Henderson Group PLC
10,511,166 sh · $425.7M
11.38%
-0.8%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Travere beats expectations, history suggests the stock could rise by around 0.68%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further clarity.

Miss

A miss could lead to a decline, with historical patterns indicating a potential drop of around 1.10%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or pipeline developments.
2Management's commentary on market conditions and competitive landscape.
3Details on revenue growth strategies and targets.
4Insights into patient feedback on existing therapies.
5Future guidance on EPS and revenue expectations.